Cytek Biosciences reaffirms its 2024 revenue guidance, expecting full year 2024 revenue in the range of $203 million to $213 million, representing growth of 5% to 10% over full year 2023, assuming no change in currency exchange rates. For the year ending December 31, 2024, Cytek Biosciences expects to report positive net income.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.3 USD | -2.21% |
|
-5.53% | -41.89% |
12/06 | Cytek Biosciences to Seek M&A | CI |
12/06 | Transcript : Cytek Biosciences, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 09:20 AM |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-41.89% | 696M | |
+5.16% | 213B | |
+9.62% | 188B | |
+31.18% | 157B | |
+33.37% | 113B | |
+3.57% | 64.85B | |
+20.08% | 55.17B | |
+1.51% | 49.1B | |
-4.27% | 38.83B | |
+0.88% | 35.6B |
- Stock Market
- Equities
- CTKB Stock
- News Cytek Biosciences, Inc.
- Cytek Biosciences, Inc. Reaffirms Earnings Guidance for the Year Ending December 31, 2024